Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.

ABSTRACT:

Aim

To assess selected cardiorenal outcomes with ertugliflozin according to use of baseline glucose-lowering agent.

Materials and methods

VERTIS CV was a cardiovascular (CV) outcome trial for ertugliflozin versus placebo, conducted in patients with type 2 diabetes and established atherosclerotic CV disease. The primary outcome was time to the first event of CV death, myocardial infarction or stroke (major adverse CV events [MACE]), with other CV outcomes also assessed. Outcomes were analysed using Cox proportional hazards models stratified by baseline use of metformin, insulin, sulphonylureas (SUs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, with interaction testing to assess for treatment effect modification. Changes from baseline in glycaemic, metabolic and haemodynamic

SUBMITTER: Dagogo-Jack S 

PROVIDER: S-EPMC9314942 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature